AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 192 min read$SILO

Silo Pharma, Inc. (SILO): Entry into a Material Definitive Agreement

Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting LLC (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Compan

Original reporting
SEC EDGAR 8-K
Published Aug 19, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$SILO
Bullish
medium confidence
Mentioned
$SILO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SILOBullishMed
01

Why it matters

The asset purchase adds proprietary software to Silo's offerings, potentially enhancing its competitive position.

02

Market read

First disclosure of a strategic asset acquisition for Silo Pharma, offering a new catalyst for the stock.

03

What to watch

Potential integration challenges and valuation of the acquired software assets.

Relevance 6/10Novelty 8/10Timing: effective August 18, 2026

Background

Silo Pharma filed an 8‑K reporting a material definitive agreement and unregistered equity sales.

Company-level read

Ticker impact

$SILOBullishMedium confidence
Context

Silo Pharma entered into an Asset Purchase Agreement to acquire software and related IP from Parkview Consulting LLC.

Expected impact

Potential modest upside as investors price in the strategic asset acquisition.

Evidence & confidence

The deal is material but the purchase price is paid in shares, limiting immediate cash impact.

Market effects

Sector

May signal increased M&A activity in the biotech software niche.

Regional

Limited to U.S. biotech sector.

Global

Low global impact beyond niche investors.

Counterpoint

What could challenge this read

The share‑based purchase could dilute existing shareholders without immediate cash benefit.

Key entities

  • Company
    Silo Pharma, Inc.

    Biotech firm acquiring software assets.

  • Company
    Parkview Consulting LLC

    Seller of the software and related intellectual property.

Read at source← All news

Related articles

JUL 10
$SILOMed

Silo Pharma Sinks on Stock Sale

Silo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.

baystreet.ca2 min
JUL 10
$SILOMedAI 8/10

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.

manilatimes.net4 min
JUL 10
$SILOMedAI 8/10

Silo Pharma, Inc.: Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement priced at-the-market under Nasdaq rules for 619,965 shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to buy up to 619,965 shares each. Price is $6.452 per share, with $6.21 warrant exercise. Gross proceeds are about $4M upfront, up to $7.7M if warrants are fully exercised in cash. Net proceeds for working capital and general corporate purposes.

finanznachrichten.de3 min
JUL 10
$METAHighAI 8/10

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall By Investing.com

U.S. stock index futures were mixed premarket on Friday, with S&P 500 futures flat and Nasdaq 100 futures down 0.3% by 08:25 ET. CCC Intelligent Solutions rose 14.5% on a Reuters report it is exploring a sale with Morgan Stanley. Circle gained 7% after OCC approval for a digital currency bank. Meta rose 3.8% on a new AI model. Fermi America fell 14.6% after pricing $375m convertible notes, and Silo Pharma dropped 22% on an up to $11.7m ATM placement.

investing.com3 min
JUL 10
$SILOHighAI 9/10

Silo Pharma stock tumbles 22% on dilutive private placement By Investing.com

Silo Pharma (NASDAQ:SILO) shares dropped 22% after the company announced an up to $11.7 million private placement under Nasdaq rules. It plans to issue 619,965 shares plus Series A-3 and A-4 warrants for up to 619,965 shares each at $6.452 per share. Expected gross proceeds are about $4 million upfront, with up to about $7.7 million more if warrants are exercised.

investing.com4 min
SEP 5
$SPWRHigh

SunPower Shares Fall 17.2% Following $26.2 Million Private Placement

SunPower Inc (SPWR) shares dropped 17.2% in pre-market trading after announcing a $26.2 million private placement at $0.2541 per share, below the previous close of $0.402. The deal adds 103.1 million shares, diluting existing shareholders. CEO T.J. Rodgers cited market changes and operational issues. SunPower had $4M in cash and negative equity at Q2 2026 end.

yahoo.com2 min